On the recordNovember 29, 2011
None of the reasons that the FDA cites are due to pricing issues, and certainly none of them are related to 340(b).
Source
congress.govChris Murphy: “None of the reasons that the FDA cites are due to pricing issues, and certainly none of them are related to 340(b).”
Editor's note · Context
Murphy asserts that pricing is not a cause of drug shortages according to the FDA.
Share
More from Chris Murphy
Oct 7, 2026
It’s important for members of the Senate to see the damage that has been done to U.S. facilities firsthand… I’m meeting with regional partners, in particular the Qataris and the Saudis, to talk about the impact of the Iran War… and to pull…
Oct 8, 2026
It’s important for the Crown Prince to hear not just from the Trump Administration, but from people who want a different path.
Oct 8, 2026
It’s important to recognize there are things we need to work on together: ending the war in Iran and a pathway to Palestinian statehood.
Oct 7, 2026
This should be unacceptable to every member of Congress—Republicans and Democrats—and this should be unacceptable to the American public.
Other voices in this conversation
